David D. Ho, MD, RenBio Co-founder
                    Yaoxing Huang, PhD, RenBio Co-founder

Meet RenBio's co-founders

David D. Ho, MD and
Yaoxing Huang, PhD

Drs. Ho and Huang have collaborated on several successful scientific projects over more than 25 years and have advanced multiple vaccine and antibody candidates from the bench to the bedside. RenBio is the fruition of their latest collaborative endeavor.


David D. Ho, MD

David D. Ho, MD

Dr. Ho is the Founding Scientific Director of the Aaron Diamond AIDS Research Center and the Clyde and Helen Wu Professor of Medicine at Columbia University Vagelos College of Physicians and Surgeons. He has been at the forefront of AIDS research since the beginning of the epidemic and is a world-renowned infectious disease physician-scientist with over 500 scientific publications including those in Nature, Science, Cell, New England Journal of Medicine and Proceedings of the National Academy of Sciences. His seminal studies unveiling the dynamic nature of HIV replication in vivo have revolutionized our basic understanding of the disease.

This knowledge led him to champion the groundbreaking approach of combination antiretroviral therapy that resulted in unprecedented control of HIV among patients. To date, more than 20 million patients worldwide have benefitted from combination antiretroviral therapy. As a major driving force in the fight to end the disease, Dr. Ho has received numerous honors and awards for his scientific accomplishments from his academic peers, national governments and the public at large. He is the recipient of a Presidential Citizens Medal, as well as 14 honorary doctorates. In addition to his election to the American Academy of Arts and Sciences and the National Academy of Medicine, he was recognized as Time magazine’s “Man of the Year” in 1996.

Yaoxing Huang, PhD

Yaoxing Huang, Ph.D.

Dr. Huang is currently an Associate Professor of Medical Sciences at Columbia University Vagelos College of Physicians and Surgeons and has spent over 25 years conducting HIV research. He has authored over 45 publications on HIV pathogenesis, vaccine discovery and development, and antibody engineering and development. Dr. Huang has led or contributed to the discovery, characterization, and preclinical development of numerous therapeutic candidates including a DNA vaccine, attenuated viral vector vaccine, and antibody therapeutic for the prevention or treatment of HIV that were all selected for advancement to clinical evaluation.



Rachel Liberatore, PhD, President & Chief Scientific Officer

Rachel A. Liberatore, Ph.D.

President & Chief Scientific Officer

Marek Drozdz, PhD, Director of Research

Marek M. Drozdz, Ph.D.

Director of Research

Annelyn O’Rourke, Director of Finance & Human Resources

Annelyn P. O’Rourke, CPA

Director of Finance & Human Resources

Andrew Cameron, M.S., Senior Research Engineer

Andrew D. Cameron, M.S.

Senior Research Engineer I

Delcora Campbell, M.S., Research Associate

Delcora A. Campbell, M.S.

Research Associate II

Debnath Maji, PhD, Senior Research Engineer

Debnath Maji, Ph.D.

Senior Research Engineer I

Robert Miller, Director of Development

Robert Miller

Director of Development

Maushumi Rahman, Staff Accountant

Maushumi Rahman

Accounts Payable and Grants Manager

Linda Sasset, PhD, Research Scientist

Linda Sasset, Ph.D.

Research Scientist II

Andy Thompson, Lab Manager

Andy T. Thompson

Research Associate II

Carleigh Sussman, Research Associate

Carleigh Sussman

Research Associate II

Krystal Ramos, Administrative Assistant

Krystal Ramos

Executive Assistant

Key Advisors and Consultants

Jim Ackland, RenBio's Partner

Jim Ackland

Martin Markowitz, M.D., RenBio's Partner

Martin Markowitz, M.D.

Meredith Brown-Tuttle, FRAPS, RenBio's Partner

Meredith Brown-Tuttle, FRAPS

Sheila Ramerman, RAC-US, RAC-Devices, RenBio's Partner

Sheila Ramerman, RAC-US, RAC-Devices

Thanos Papaïoannou, Ph.D.

Thanos Papaïoannou, Ph.D.